SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

A recent study conducted in Sweden found that GLP-1 agonists such as Ozempic and Wegovy may help reduce alcohol consumption and related harms in individuals diagnosed with alcohol use disorder. Here ...

New research has found that certain types of medication used to treat diabetes may be effective in reducing alcohol use. The study looked at whether a type of diabetes medication, called GLP-1 ...

GLP-1 agonist drugs like Ozempic, and SLGT2 inhibitor drugs like Jardiance have been linked with a lower risk of a second ...

GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

A new study provides more evidence that GLP-1 RAs don’t raise the risk for pancreatic cancer and may in fact offer some protection.

For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced mortality, myocardial ...

A total of 20,146 patients with nephrolithiasis and type 2 diabetes, including those with gout at baseline, initiated an SGLT ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

A recent study has shown that the weight-loss drug Ozempic, along with other medications in its class, may significantly ...

The weight-loss drug Ozempic can help reduce stroke patients' risk of a heart attack or death, a new study says.

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...